• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Likarda, Inc

Monday, June 03, 2024
CP
Platform for Therapeutics
Likarda has pioneered a groundbreaking platform for hydrogel delivery systems, offering both long- and short-term solutions that can either provide complete immune-protection or degrade gradually. This innovation enables precise localized therapy delivery without the need for immunosuppression, effectively addressing critical gaps in cell therapy. Our CSS Platform significantly enhances therapy efficacy by targeting specific areas, reducing off-target effects, and minimizing the required cell numbers for a therapeutic dose. In essence, Likarda's innovative hydrogel platform revolutionizes cell therapy delivery, addressing challenges in storage, shipping, and targeted delivery while offering scalable, cost-effective solutions.
Likarda, Inc
Company Website: http://Http://www.likarda.com
Lead Product in Development: Cell therapy delivery system for osteoarthritis and cancer and off-the-shelf solution for logistics and cryopreservation.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5 Animal Health Products and 2 Human Health Products

Company HQ City

Kansas City

Company HQ State

Missouri

Company HQ Country

United States

CEO/Top Company Official

Stella K. Vnook, PhD

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS